254 related articles for article (PubMed ID: 20072781)
1. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice.
Kamens HM; Andersen J; Picciotto MR
Psychopharmacology (Berl); 2010 Mar; 208(4):613-26. PubMed ID: 20072781
[TBL] [Abstract][Full Text] [Related]
2. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption.
Hendrickson LM; Zhao-Shea R; Pang X; Gardner PD; Tapper AR
J Neurosci; 2010 Jul; 30(30):10169-76. PubMed ID: 20668200
[TBL] [Abstract][Full Text] [Related]
3. Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption.
Hendrickson LM; Gardner P; Tapper AR
Channels (Austin); 2011; 5(2):124-7. PubMed ID: 21239887
[TBL] [Abstract][Full Text] [Related]
4. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Ortiz NC; O'Neill HC; Marks MJ; Grady SR
Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
[TBL] [Abstract][Full Text] [Related]
5. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats.
Bito-Onon JJ; Simms JA; Chatterjee S; Holgate J; Bartlett SE
Addict Biol; 2011 Jul; 16(3):440-9. PubMed ID: 21392178
[TBL] [Abstract][Full Text] [Related]
6. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
Steensland P; Simms JA; Holgate J; Richards JK; Bartlett SE
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12518-23. PubMed ID: 17626178
[TBL] [Abstract][Full Text] [Related]
7. Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.
Chatterjee S; Steensland P; Simms JA; Holgate J; Coe JW; Hurst RS; Shaffer CL; Lowe J; Rollema H; Bartlett SE
Neuropsychopharmacology; 2011 Feb; 36(3):603-15. PubMed ID: 21048701
[TBL] [Abstract][Full Text] [Related]
8. Promoting activity of (α4)
Wang J; Blasio A; Chapman HL; Doebelin C; Liaw V; Kuryatov A; Giovanetti SM; Lindstrom J; Lin L; Cameron MD; Kamenecka TM; Pomrenze MB; Messing RO
Neuropsychopharmacology; 2020 Jan; 45(2):301-308. PubMed ID: 31394567
[TBL] [Abstract][Full Text] [Related]
9. Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.
Hussmann GP; DeDominicis KE; Turner JR; Yasuda RP; Klehm J; Forcelli PA; Xiao Y; Richardson JR; Sahibzada N; Wolfe BB; Lindstrom J; Blendy JA; Kellar KJ
J Neurochem; 2014 May; 129(4):721-31. PubMed ID: 24422997
[TBL] [Abstract][Full Text] [Related]
10. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens.
Feduccia AA; Simms JA; Mill D; Yi HY; Bartlett SE
Br J Pharmacol; 2014 Jul; 171(14):3420-31. PubMed ID: 24628360
[TBL] [Abstract][Full Text] [Related]
11. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
[TBL] [Abstract][Full Text] [Related]
12. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.
Crunelle CL; Miller ML; Booij J; van den Brink W
Eur Neuropsychopharmacol; 2010 Feb; 20(2):69-79. PubMed ID: 19959340
[TBL] [Abstract][Full Text] [Related]
13. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
14. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.
Maggio SE; Saunders MA; Baxter TA; Nixon K; Prendergast MA; Zheng G; Crooks P; Dwoskin LP; Slack RD; Newman AH; Bell RL; Bardo MT
Psychopharmacology (Berl); 2018 May; 235(5):1439-1453. PubMed ID: 29455292
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.
Caldarone BJ; Wang D; Paterson NE; Manzano M; Fedolak A; Cavino K; Kwan M; Hanania T; Chellappan SK; Kozikowski AP; Olivier B; Picciotto MR; Ghavami A
Psychopharmacology (Berl); 2011 Sep; 217(2):199-210. PubMed ID: 21487659
[TBL] [Abstract][Full Text] [Related]
16. Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats.
Sotomayor-Zárate R; Gysling K; Busto UE; Cassels BK; Tampier L; Quintanilla ME
Psychopharmacology (Berl); 2013 May; 227(2):287-98. PubMed ID: 23344555
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
18. Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice.
Kamens HM; Silva C; Peck C; Miller CN
Brain Res Bull; 2018 Apr; 138():20-25. PubMed ID: 28778837
[TBL] [Abstract][Full Text] [Related]
19. The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.
Wildeboer-Andrud KM; Stevens KE
Pharmacol Biochem Behav; 2011 Nov; 100(1):17-24. PubMed ID: 21763340
[TBL] [Abstract][Full Text] [Related]
20. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization.
Moretti M; Zoli M; George AA; Lukas RJ; Pistillo F; Maskos U; Whiteaker P; Gotti C
Mol Pharmacol; 2014 Sep; 86(3):306-17. PubMed ID: 25002271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
